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Abstract
Background: Sepsis is a leading cause of death in intensive care units and is
increasing in incidence. Current trials of novel therapeutic approaches for sepsis
focus on 28-day mortality as the primary outcome measure, but excess mortality
may extend well beyond this time period.
Methods: We used relative survival analysis to examine excess mortality in a
cohort of 1,028 patients admitted to a tertiary referral hospital with sepsis during
2007–2008, over the first 5 years of follow up. Expected survival was estimated
using the Ederer II method, using Australian life tables as the reference population.
Cumulative and interval specific relative survival were estimated by age group, sex,
sepsis severity and Indigenous status.
Results: Patients were followed for a median of 4.5 years (range 0–5.2). Of the
1028 patients, the mean age was 46.9 years, 52% were male, 228 (22.2%) had
severe sepsis and 218 (21%) died during the follow up period. Mortality based on
cumulative relative survival exceeded that of the reference population for the first 2
years post admission in the whole cohort and for the first 3 years in the subgroup
with severe sepsis. Independent predictors of mortality over the whole follow up
period were male sex, Indigenous Australian ethnicity, older age, higher Charlson
Comorbidity Index, and sepsis-related organ dysfunction at presentation.
Conclusions: The mortality rate of patients hospitalised with sepsis exceeds that
of the general population until 2 years post admission. Efforts to improve outcomes
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from sepsis should examine longer term outcomes than the traditional primary
endpoints of 28-day and 90-day mortality.
Introduction
Severe sepsis is the most common cause of death in intensive care units [1], and
its incidence has progressively increased over the past 20 years [2, 3]. Until
recently, most clinical trials of new therapeutic approaches for severe sepsis have
used 28-day mortality as their primary endpoint [4–6]. However, it is now
increasingly recognised that the sequelae of sepsis extend well beyond the index
hospitalisation and that longer-term outcomes should be used in order to better
understand the effect of a given intervention [7, 8]. Despite this increased recent
interest, it remains unclear how long the excess mortality risk persists after an
episode of severe sepsis, with estimates ranging from 90 days to 5 years [8–13].
Most existing studies investigating longer-term outcomes of sepsis are difficult
to extrapolate for several reasons. The majority of sepsis outcome studies include
only patients admitted to an intensive care unit (ICU), but only 50–70% of
patients hospitalised with severe sepsis ever enter an ICU [14, 15]. Most of these
studies use retrospective analysis of existing large datasets, potentially under-
estimating the true incidence of sepsis [16]. Most importantly, with rare
exceptions [13], these studies generally do not compare sepsis outcomes with
those of an appropriately matched general population.
Relative survival analysis is a statistical technique commonly used in oncology
[17–19], but it has very rarely been applied to sepsis outcomes [20]. It compares
the survival of a cohort of patients over time with that of a background reference
population.
We aimed to describe the long term outcomes of a prospectively recruited
cohort of patients with sepsis, including those admitted to ICU and non-ICU
wards. Our primary aim was to estimate the duration of the excess mortality risk




The patients included in this cohort have been previously described in detail [21].
In brief, we prospectively enrolled every patient admitted over a 365 day period in
2007–2008 who met the 1992 ACCP-SCCM criteria for sepsis [22], in a tertiary
referral hospital in tropical Australia.
Where patients were admitted with more than one episode of sepsis over the
12-month course of the original study, only the first episode was included in the
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current analysis. Furthermore, all patients who were resident outside the Northern
Territory in the year of initial admission (n562) were excluded from the current
analysis, because their vital status was difficult to determine accurately in the
longer term.
Ethics approval
This study was approved by the Human Research Ethics Committee of the
Menzies School of Health Research and Northern Territory Department of
Health, who waived the requirement for individual informed consent.
Definitions
Severe sepsis was defined as sepsis plus at least one attributable organ dysfunction
within the previous 24 hours, as per the definitions used in the PROWESS study
[4]. Comorbidities were as defined by Charlson et al and quantified using the
Charlson Comorbidity Index [23].
Outcomes
Information about all deaths that occur in the Northern Territory is provided to
the Northern Territory Department of Health by the Registrar of Births, Deaths
and Marriages and recorded in the public hospitals’ client administration system.
We accessed this deaths information to determine vital status for all patients
included in this study at 12 months, 3 years and 5 years after the commencement
of the study.
Survival analysis
Patients were included in the survival model until death from any cause, censoring
due to loss to follow up, or the end of the follow-up period (30/06/2012).
Mortality of sepsis patients was measured as both overall survival and relative
survival. Overall survival (also referred to as crude survival) is the proportion of
sepsis patients still alive at a certain point in time after their sepsis episode; deaths
include those unrelated to the sepsis episode, so overall survival does not measure
excess mortality related specifically to the sepsis episode. Overall survival analysis
was calculated using the Kaplan-Meier method.
By comparing deaths among the sepsis patients with the expected number of
deaths based on general population mortality rates, relative survival is an estimate
of excess mortality in the sepsis patients. To estimate relative survival, the
background mortality rate for the general population was derived from life tables.
Expected survival was estimated using the Ederer II method [24] from Australian
population life tables for non-Indigenous people and life tables for the total NT
Indigenous population for Indigenous people, stratified by age, sex and calendar
period. At the time of analysis, life table data were only available up until 2006,
therefore, expected survival for the study period were based on 2006 data. The
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results of relative survival analysis were expressed in several ways: one-year and
five-year relative survival; interval-specific relative survival; and the excess
mortality rate. Cumulative relative survival is the observed survival among the
subjects under study at a point in time after their first sepsis episode divided by
the expected survival of people of the same age, sex and Indigenous status in the
general population; for example, five-year relative survival is the cumulative
relative survival at five years after first sepsis episode [24]. In general, cumulative
relative survival progressively decreases over time since the first episode until there
is no more attributable excess mortality of the condition of interest (relative to the
background population), after which it plateaus at a constant level. Interval-
specific relative survival is the ratio of the survival in the population of interest
relative to the general population during specific time intervals. Interval-specific
relative survival is lower than 1.0 when the survival of the study cohort is lower
than expected (based on the mortality rates of the general population) and
plateaus at 1.0 when the survival of the cohort becomes the same as the
background population. The excess mortality rate is the difference between the
observed mortality rate in the subjects and the expected rate based on that of the
general population(matched for age, sex and Indigenous status) [25].
Statistical analysis
All analyses were conducted using Stata/SE 12 (StataCorp, College Station, TX).
Continuous variables were compared using t-test for normally distributed data
and Mann-Whitney U test for non-normal data. Categorical variables were
compared using x2 test. Crude survival rates were derived using Kaplan-Meier
estimates. Interval-specific relative survival ratio (RSR) and cumulative RSR were
derived using the Stata user-defined program ‘‘strs’’ [26] and excess mortality
rates were derived using flexible parametric models, fitted using the Stata user-
defined program ‘‘stpm2’’ [25].
A generalized linear model with Poisson error structure was used to model the
excess mortality based on collapsed data, in which the outcome was the observed
number of deaths and was assumed to be Poisson distributed. The predictors of
excess mortality were chosen using forward selection, resulting in the final model
with the following covariates: follow-up time since diagnosis, gender, Indigenous
status, age group, Charlson index group, severe sepsis and bacteraemic.
Results
Patient demographics and outcomes
Patients were followed for a median of 4.5 years (range 0–5.2 years), giving a
cumulative time at risk of 3,997 patient-years. Of the 1,028 patients with sepsis,
218 had died by the end of the follow-up period. Severe sepsis was present in 228
patients (22% - Table 1). Those who died during the follow up period were older,
more likely to be male and Indigenous, had greater sepsis severity at baseline and a
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larger number of co-morbidities. Pneumonia was over-represented amongst those
who died, and skin and soft tissue infection was under-represented (Table 1).
Crude survival analysis
One-year and five-year crude survival for all sepsis patients (with 95% confidence
intervals) were 87.5% (85.3%–89.3%), and 77.6%(74.5%–80.4%) respectively.
The corresponding figures for the severe sepsis subgroup were 74.1% (67.9%–
79.3%) and 66.2% (59.7%–72.0%).
Table 1. Demographics, comorbidities, characteristics of infection and disease severity in those who died compared with those who were alive at the end of
follow up.
Total (n51,028) Died (n5218) Alive (n5810) P valuea
Predisposition
Age (years)b 46.9 (17.3) 58.9 (15.7) 43.6 (16.2) ,0.001
Male 532 (51.8%) 128 (58.7%) 404 (49.9%) 0.02
Indigenous 510 (49.6%) 128 (58.7%) 382 (47.2%) ,0.001
Hazardous alcohol usec 284/636 (44.7%) 70/133 (52.6%) 214/503 (42.5%) 0.04
Current smokingc 329/694 (47.4%) 69/139 (49.6%) 296/555 (53.3%) 0.44
Chronic renal disease 122 (11.9%) 54 (24.8%) 68 (8.4%) ,0.001
Chronic liver disease 79 (7.7%) 32 (14.7%) 47 (5.8%) ,0.001
Diabetes 250 (24.3%) 81 (37.2%) 169 (20.9%) ,0.001
COPD 135 (13.1%) 54 (24.8%) 81 (10.0%) ,0.001
Malignancy 44 (4.3%) 22 (10.1%) 22 (2.7%) ,0.001
Charlson comorbidity indexd 1 (0–2) 3 (1–4) 0 (0–1) ,0.001
Infection
Bacteraemic 163 (15.8%) 61 (28.0%) 102 (12.6%) ,0.001
Pneumonia 317 (30.8%) 96 (44.0%) 221 (27.3%) ,0.001
Urosepsis 122 (11.9%) 34 (15.6%) 88 (10.9%) 0.06
Skin and soft tissue infection 349 (34.0%) 43 (19.7%) 306 (37.8%) ,0.001
Intra-abdomnal infection 109 (10.6%) 17 (7.8%) 92 (11.4%) 0.13
Gram positive bacterium 255 (24.8%) 50 (22.9%) 205 (25.3%) 0.47
Gram negative bacterium 205 (19.9%) 50 (22.9%) 155 (19.1%) 0.21
Response and Organ Dysfunction
Required ICU admission 161 (15.7%) 62 (28.4%) 99 (12.2%) ,0.001
Severe sepsis 228 (22.2%) 77 (35.3%) 151 (18.6%) ,0.001
APACHE II scored 8 (4–13) 14 (9–20) 6 (3–10) ,0.001
SOFA scored 1 (0–3) 3 (1–5) 1 (0–2) ,0.001
Data are given as n(%) unless stated otherwise.
Parameters are grouped according to PIRO classification [39].
aP-value comparing those alive at end of follow up period compared with those who were not.
bMean (SD).
cData were not available for all patients regarding alcohol use and smoking.
dMedian (IQR).
doi:10.1371/journal.pone.0112224.t001
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Fig. 1. a. Kaplan-Meier crude survival estimates by age group for all sepsis patients (n51,028). b. Kaplan-
Meier crude survival estimates by age group for severe sepsis patients (n5228).
doi:10.1371/journal.pone.0112224.g001
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Kaplan-Meier estimates by age group are shown in Fig. 1, in which people aged
over 64 years had the lowest crude survival and people under 45 years old had the
highest.
Relative survival analysis
Figs. 2a and 2b show cumulative relative survival by age group for the overall
cohort and those with severe sepsis. For the whole cohort, the curve plateaus after
approximately 2 years (Fig. 2a), and for those with severe sepsis, it plateaus at 3
years (Fig. 2b). This indicates that the excess mortality persists for 2 years in
sepsis patients, and 3 years in those with severe sepsis, after which sepsis patients
have a mortality rate similar to that of the general population. The relative
survival of sepsis patients was worse in older age groups, and this difference was
most marked in the first 6 months after presentation (Figs. 3a and 3b).
Interval-specific relative survival (Tables 2 and 3) lead to a similar conclusion –
survival of the sepsis cohort is lower than that of the general population in each
period until approximately 2 years after diagnosis, and that of the severe sepsis
subgroup until 3 years.
Across all subgroups except males greater than 64 years old, Indigenous patients
had lower five-year relative survival than non-Indigenous patients (Table 4), with
this difference being most evident in young female patients. Across all age groups,
females had higher five-year relative survival than males.
Multivariable analysis of predictors of mortality
In multivariable regression analysis, (Table 5) excess mortality was highest in the
first year and decreased over time after the sepsis episode, dropping to almost zero
(relative to the first year) in the fourth and fifth years of follow-up. Other
independent predictors of excess mortality were male sex, Indigenous ethnicity,
older age, more comorbidities and sepsis-related organ dysfunction at presenta-
tion.
Discussion
In this cohort of patients hospitalised with sepsis, and including approximately
4,000 patient years of follow up, the excess mortality persisted for 2 years overall
and for 3 years in the subgroup with severe sepsis.
Although there is increasing interest in longer term outcomes following sepsis
[8–11], the use of relative survival analysis is rare in the sepsis literature. Our
study differs from the only previous publication to use relative survival analysis in
a sepsis cohort [20] in several ways. In contrast to the prospective design of our
study, the study by Ghelani was retrospective, with sepsis defined using ICD-9
coding, which decreases both the sensitivity and specificity of the diagnosis of
sepsis compared with prospective methods. Ghelani et al found that the
cumulative relative survival in the ICU sepsis cohort continued to decline over the
Long Term Outcomes in Sepsis Patients Using Relative Survival Analysis
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Fig. 2. a. Cumulative relative survival for patients with sepsis and severe sepsis, compared with a reference
population. Dotted lines represent 95% confidence intervals. b. Cumulative relative survival for only patients
with severe sepsis (n5228), compared with a reference population. Dotted lines represent 95% confidence
intervals.
doi:10.1371/journal.pone.0112224.g002
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entire follow up period (range 4.2–9.6 years), never reaching a plateau. This is in
contrast to our finding of a plateau occurring after 2 years, and is difficult to
explain. Ghelani’s finding implies that the excess risk of death following a sepsis
episode never abates, suggesting that the characteristics of the population are
responsible rather than the insults of the sepsis episode.
Fig. 3. a. Cumulative relative survival by age group for all sepsis patients (n51,028). b. Cumulative relative
survival by age group for severe sepsis patients (n5228).
doi:10.1371/journal.pone.0112224.g003
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Although we have demonstrated excess mortality in the sepsis cohort compared
to the general population, we cannot determine the mechanism of mortality, as we
did not have access to cause of death data. Acute sepsis-related organ failure
generally resolves by the time of hospital discharge in those who survive. However,
systemic inflammatory activation persists for weeks-months afterwards [27], as
does functional immunosuppression [28, 29]. Systemic inflammation is associated
with endothelial cell activation and dysfunction and an increase in endogenous
nitric oxide inhibitors [30–33] [34, 35] which are turn associated with acute
vascular events [36, 37] and increased early mortality in sepsis [38]. Hence delayed
secondary infections and vascular events are plausible potential explanations for
this observed excess mortality. An alternative explanation is that patients
hospitalised with sepsis may differ from the background population in important
comorbidities such as diabetes mellitus, excess alcohol use and chronic renal
disease. Our data do not provide evidence to distinguish between these two
Table 2. Interval-specific relative survival by age category (all sepsis patients).
Time period (years of follow up) Interval-specific relative survival (95% CI)
Overall Age 15–44 Age 45–64 Age.565
0–0.5 0.90 (0.88–0.92) 0.95 (0.93–0.97) 0.90 (0.87–0.93) 0.78 (0.71–0.83)
0.5–1.0 0.98 (0.97–0.99) 0.99 (0.98–1.00) 0.97 (0.97–0.99) 0.98 (0.93–1.00)
1.0–1.5 0.97 (0.96–0.98) 0.99 (0.97–1.00) 0.97 (0.95–0.99) 0.92 (0.85–0.96)
1.5–2.0 0.99 (0.98–1.00) 1.00 (0.98–1.00) 0.99 (0.97–1.00) 0.94 (0.87–0.98)
2.0–2.5 1.00 (0.99–1.00) 1.00 (1.00–1.00) 0.99 (0.97–1.00) 1.00 (0.94–1.02)
2.5–3.0 0.99 (0.98–1.00) 1.00 (1.00–1.00) 0.99 (0.96–1.00) 0.95 (0.88–0.99)
3.0–3.5 1.00 (0.99–1.00) 1.00 (1.00–1.00) 1.00 (0.98–1.00) 1.00 (0.94–1.02)
3.5–4.0 1.00 (0.99–1.00) 1.00 (0.98–1.00) 1.00 (0.98–1.00) 1.01 (0.94–1.02)
4.0–4.5 1.00 (0.99–1.00) 1.00 (1.00–1.00) 0.99 (0.97–1.00) 0.98 (0.90–1.01)
4.5–5.0 1.00 (0.98–1.00) 0.99 (0.96–1.00) 1.00 (0.95–1.01) 1.03 (1.03–1.03)
doi:10.1371/journal.pone.0112224.t002
Table 3. Interval specific relative survival by age category (severe sepsis patients).
Time period (years of follow up) Interval–specific relative survival (95% CI)
Overall Age 15–44 Age 45–64 Age.565
0–0.5 0.77 (0.70–0.82) 0.87 (0.78–0.93) 0.76 (0.66–0.84) 0.57 (0.41–0.70)
0.5–1.0 0.98 (0.95–1.00) 0.99 (0.91–1.00) 0.98 (0.90–1.00) 0.98 (0.77–1.02)
1.0–1.5 0.97 (0.92–0.99) 0.99 (0.91–1.00) 0.95 (0.86–0.98) 0.94 (0.73–1.00)
1.5–2.0 0.98 (0.94–1.00) 0.99 (0.91–1.00) 1.01 (1.01–1.01) 0.89 (0.66–0.98)
2.0–2.5 0.99 (0.96–1.00) 1.00 (1.00–1.00) 0.99 (0.90–1.00) 0.97 (0.71–1.01)
2.5–3.0 0.99 (0.95–1.00) 1.00 (1.00–1.00) 0.96 (0.87–0.99) 1.02 (1.02–1.02)
3.0–3.5 1.00 (0.96–1.01) 1.00 (1.00–1.00) 1.01 (1.01–1.01) 0.97 (0.70–1.02)
3.5–4.0 1.00 (0.96–1.01) 0.99 (0.91–1.00) 1.01 (1.01–1.01) 1.03 (1.03–1.03)
4.0–4.5 1.01 (1.01–1.01) 1.00 (1.00–1.00) 1.01 (1.01–1.01) 1.03 (1.03–1.03)
4.5–5.0 1.01 (1.01–1.01) 1.00 (1.00–1.00) 1.01 (1.01–1.01) 1.03 (1.03–1.03)
doi:10.1371/journal.pone.0112224.t003
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explanations because the background population life tables used in the relative
survival analysis were not stratified by co-morbidity. However, a previous large
study by Quartin et al. comparing sepsis patients with a control hospitalised
population found that the excess mortality in the sepsis group lasted for at least 5
years, and persisted even after adjustment for comorbidities [13]. This suggests
either that the mortality excess which persists beyond the acute period is related to
the sepsis episode itself rather than to underlying comorbidities, or that
unmeasured comorbidities or characteristics are responsible for excess mortality,
as suggested by Ghelani’s data [20] Neither our study nor previously published
work can definitively determine whether excess mortality in sepsis patients is due
to sepsis itself, underlying comorbidities, or a combination of the two.
Our finding that excess mortality persists for at least 2–3 years supports calls to
extend the traditional end-points of interventional sepsis studies beyond the most
commonly used end-point 28-day mortality [7]. Further work is needed to
identify the aetiology of the excess mortality following hospital admission for
sepsis, particularly that which occurs more than 1 year post discharge.
Table 4. Five-year relative survival (with 95% confidence interval) by age group, sex and Indigenous status.
Gender Age-group Non-Indigenous Indigenous
Male 15–44 years 0.98 (0.92–1.00) 0.89 (0.78–0.96)
45–64 years 0.90 (0.82–0.95) 0.75 (0.63–0.85)
.565 years 0.55 (0.42–0.67) 0.57 (0.26–0.89)
Female 15–44 years 1.00 (1.00–1.00) 0.86 (0.77–0.92)
45–64 years 0.93 (0.83–0.98) 0.74 (0.63–0.83)
.565 years 0.77 (0.54–0.94) 0.72 (0.48–0.92)
doi:10.1371/journal.pone.0112224.t004
Table 5. Multivariable analysis of predictors of excess mortality using Poisson regression.
Variable Adjusted hazard ratio 95% CI P-value
Year of follow-up: 2 0.35 0.22 0.54 ,0.001
Year of follow-up: 3 0.12 0.05 0.29 ,0.001
Year of follow-up: 4 0.04 0.00 0.25 0.001
Year of follow-up: 5a 0.04 0.00 0.65 0.02
Maleb 1.58 1.10 2.27 0.01
Indigenousc 1.56 1.05 2.31 0.03
Age group: 45–64d 1.68 1.04 2.73 0.03
Age group:.565d 3.40 2.02 5.72 ,0.001
Charlson index 1–2e 3.82 1.90 7.69 ,0.001
Charlson index.53e 11.98 6.05 23.74 ,0.001
Severe Sepsisf 2.30 1.61 3.27 ,0.001
Bacteraemicg 1.67 1.15 2.42 0.007
Reference categories – a. First year of follow up; b. Female. c. Non-Indigenous d. Age group 15-44 years. e. Charlson comorbidity index50; f. Non-severe
sepsis patients; g. Non-bacteraemic patients.
doi:10.1371/journal.pone.0112224.t005
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Our study has some limitations. We studied a cohort of patients from tropical
Australia of whom a substantial proportion were Indigenous Australians, and with
a relatively young mean age, and thus the applicability of our findings to other
populations is unclear. However, the fact that the post-sepsis mortality excess has
been shown to persist for well beyond 90 days in several other cohorts support our
findings. We used life tables from 2006 (the most recent available robust data),
but the period under study was 2007–2012. If the mortality rate in the background
population had decreased over this time, our models may have overestimated the
excess mortality in the sepsis population. However, given the short time between
these two periods, this is unlikely to have been significant. We did not have access
to data on cause of death, nor on comorbidities in the reference population.
However, a strength of our study is that, unlike the majority of sepsis studies
investigating longer term outcomes post-sepsis [9–12], we compared the survival
of a sepsis cohort with that of an appropriate reference population.
Conclusions
In conclusion, the risk of mortality from an acute episode of sepsis extends well
beyond hospital discharge. Relative survival analysis is a useful tool for examining
the excess mortality in patients with sepsis. Future efforts to improve outcomes
from sepsis should focus on endpoints as long as 3 years post discharge, and such
endpoints should no longer be limited to the first 90 days following hospital
admission.
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